Sanofi has obtained the rights to the investigational drug Plerixafor Injection in the Greater China region from Viatris
On August 1st, biopharmaceutical company Sanofi announced that it has signed an asset purchase agreement with ViaZhen, a subsidiary of biotechnology company Arrowhead. ViaZhen is currently developing and commercializing four cardiovascular metabolic candidates from Arrowhead in the Greater China region. According to the agreement, Sanofi will obtain the rights to develop and commercialize the investigational drug Praluent sodium injection in the Greater China region
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments